Companies Dominating the Bispecific Antibody Market
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Innovent Biologics, Ltd.
- Affimed GmbH
- Pieris Pharmaceuticals, Inc.
- Mereo BioPharma Group plc
- TG Therapeutics, Inc.
- MacroGenics, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- AbbVie, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of bispecific antibody is assessed at USD 605.9 million.
The global bispecific antibody market is projected to grow from USD 576.44 million in 2024 to USD 1.44 billion by 2037, exhibiting a CAGR of over 7.3% during the forecast period, between 2025 and 2037.
North America industry is estimated to dominate majority revenue share of 35% by 2037, due to rising demand for targeted and personalized therapies in the region.
The major players in the market include F. Hoffmann-La Roche Ltd., Innovent Biologics, Ltd., Affimed GmbH, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc, TG Therapeutics, Inc., MacroGenics, Inc., Pfizer Inc., GlaxoSmithKline plc, AbbVie, Inc.
